Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 06 November 2025

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1730005

Correction: Analysis of the twelve cases of immune-related myocarditis caused by cadonilimab

  • Frontiers Media SA, Lausanne, Switzerland

A Correction on
Analysis of the twelve cases of immune-related myocarditis caused by cadonilimab

By Chen P, Zhao Z, Zheng H and Li J (2025). Front. Oncol. 15:1671973. doi: 10.3389/fonc.2025.1671973

Author “Haiyang Zheng” was erroneously assigned to affiliation “Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China”. The correct affiliation for “Haiying Zheng” is “Department of Pharmacy, Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China”.

The original version of this article has been updated.

Keywords: cadonilimab, immune-related myocarditis, cytotoxic T-lymphocyte-associated protein-4, immunotherapy, programmed cell death receptor-1 (PD-1)

Citation: Production Office F (2025) Correction: Analysis of the twelve cases of immune-related myocarditis caused by cadonilimab. Front. Oncol. 15:1730005. doi: 10.3389/fonc.2025.1730005

Received: 22 October 2025; Accepted: 22 October 2025;
Published: 06 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.